PDCD1 and leukemia: Although immunoediting was characterized by the upregulation of the immunosuppressive ligand PD-L1, anti-PD1 therapy had limited efficacy in restoring the anti-leukemia immune response in this model, suggesting that the strategy employed in the immunoedited NrasG12D AML to evade the immune system is likely to be multifaceted.